文献速递脊柱关节炎

比奇珠单抗治疗强直性脊柱炎(放射学阳性中轴型脊柱关节炎)的长期安全性与持续疗效:BE AGILE(2b期)及其开放标签扩展研究的5年结果

Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension.
PubMed 文献 · RMD Open · 2025-01-31

BE AGILE 2b期随机对照试验及其开放标签扩展研究评估了比奇珠单抗160 mg每4周一次治疗活动性放射学阳性中轴型脊柱关节炎的长期安全性和疗效。至第256周,289/303(95.4%)例患者发生至少1例治疗中出现的不良事件,最常报告的是鼻咽炎(21.8%)和上呼吸道感染(14.5%)。第48周的疗效维持至5年,第256周非应答者插补分析显示49.7%的患者达到ASAS40应答,41.6%达到ASDAS低疾病活动度。

要点

  • 比奇珠单抗治疗5年安全性特征与既往报告一致,未发现新的安全信号。
  • 真菌感染暴露调整发生率为7.4/100患者年,均为非系统性感染。
  • 第48周获得的稳健疾病控制所对应的疗效维持至第256周。

核心结论

  • 比奇珠单抗治疗5年后安全性特征与既往报告一致,未发现新的安全信号。
  • 在此放射学阳性中轴型脊柱关节炎人群中,第48周达到稳健疾病控制后,5年疗效得以维持。

研究设计与样本

  • BE AGILE 2b期剂量范围随机对照试验为期48周,完成试验的活动性放射学阳性中轴型脊柱关节炎患者可入组开放标签扩展研究。
  • 开放标签扩展研究中患者接受比奇珠单抗160 mg每4周一次,安全性和疗效结局呈现至第256周。

主要发现

  • 第0至256周,289/303(95.4%)例患者发生至少1例治疗中出现的不良事件,最常见为鼻咽炎(21.8%)和上呼吸道感染(14.5%)。
  • 真菌感染暴露调整发生率为7.4/100患者年(念珠菌感染2.6,口腔念珠菌病2.2),无系统性感染。
  • 严重感染暴露调整发生率为1.4/100患者年,未报告活动性结核。
  • 活动性炎症性肠病和葡萄膜炎暴露调整发生率分别为0.8/100患者年和0.7/100患者年。
  • 202/303(66.7%)例患者完成第256周,42(13.9%)例因治疗中出现的不良事件终止治疗。

关键数值与推荐

  • 第256周时,非应答者插补分析显示49.7%(观察病例73.1%)的患者达到ASAS40应答。
  • 第256周时,非应答者插补分析显示41.6%(观察病例71.1%)的患者达到ASDAS低疾病活动度。
  • 平均(标准误;多重插补)ASDAS从基线3.9(0.1)改善至第48周2.1(0.1),并维持至第256周。
  • 疼痛、疲劳、身体功能和健康相关生活质量的改善得以维持。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Assess long-term safety, tolerability and efficacy of bimekizumab in ankylosing spondylitis (radiographic axial spondyloarthritis (r-axSpA)). METHODS: Patients with active r-axSpA completing the dose-ranging 48-week randomised controlled trial could enrol in the open-label extension, where patients received bimekizumab 160 mg every 4 weeks. Safety (exposure-adjusted incidence rates/100 patient-years (EAIRs)) and efficacy outcomes (binary: non-responder imputation (NRI) and observed case (OC); continuous: multiple imputation (MI)) are presented through 256 weeks. RESULTS: From Weeks 0-256, 289/303 (95.4%) patients had ≥1 treatment-emergent adverse event (TEAE); most frequent were nasopharyngitis (21.8%) and upper respiratory tract infection (14.5%). The EAIR of fungal infections was 7.4 (Candida infections: 2.6; oral candidiasis: 2.2); none systemic. EAIR of serious infections was 1.4; no active tuberculosis was reported. Active inflammatory bowel disease and anterior uveitis EAIRs were 0.8 and 0.7, respectively. 202/303 (66.7%) patients completed Week 256. 42 (13.9%) patients discontinued treatment due to TEAEs.Efficacy at Week 48 was maintained for 5 years. At Week 256, NRI analysis showed 49.7% (OC: 73.1%) and 41.6% (OC: 71.1%) of patients achieved Assessment of SpondyloArthritis International Society 40% (ASAS40) response and Axial Spondyloarthritis Disease Activity Score (ASDAS) low disease activity, respectively. Mean (SE; MI) ASDAS improved from 3.9 (0.1) at baseline to 2.1 (0.1) at Week 48, which was maintained to Week 256. Improvements in pain, fatigue, physical function and health-related quality of life were sustained. CONCLUSIONS: The safety profile of bimekizumab after 5 years of treatment remained consistent with previous reports, with no new safety signals identified. 5-year efficacy was sustained in this r-axSpA population following robust disease control achieved at Week 48. TRIAL REGISTRATION NUMBERS: NCT02963506; NCT03355573.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Deodhar A, Navarro-Compán V, Poddubnyy D, et al. Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension. RMD Open. 2025. PMID: 39890205. doi:10.1136/rmdopen-2024-005081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。